PV-10

SilverBow Resources Mails Letter to Shareholders Highlighting Proven M&A Strategy Overseen by Highly Experienced Board

Retrieved on: 
월요일, 5월 6, 2024
Oil, Gas, Energy, CFO, E&P, ISS, Annual general meeting, Eagle Ford Group, Eagle Ford, Dallas, Glass Lewis, Acquisition, Corporate title, KeyBank, PV-10, Letter, Eagle, Management

SilverBow Resources, Inc. (NYSE: SBOW) (“SilverBow” or the “Company”) today mailed a letter to shareholders in connection with the Company’s 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”).

Key Points: 
  • SilverBow Resources, Inc. (NYSE: SBOW) (“SilverBow” or the “Company”) today mailed a letter to shareholders in connection with the Company’s 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”).
  • The full text of the letter follows:
    SilverBow Resources recently released outstanding first quarter financial and operating results, demonstrating the merits of our business strategy and the value that is being delivered by our prior acquisitions.
  • Our performance in the market is directly attributable to a proven strategy, strong management and an experienced Board of Directors.
  • Additionally, all nine have had board experience at other public companies, including, but not limited to, at E&P, oilfield services or midstream companies.

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Retrieved on: 
목요일, 4월 18, 2024
FDA, University, Mouse, Biochemistry, Lab, Science Publishing Group, Unique, Identification, Research, Autophagy, Molecular biology, WNK1, Pediatrics, Plasma protein binding, Narendran, PV-10, Pharmaceutical industry

KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.

Key Points: 
  • KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
  • The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors.
  • The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling.
  • In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.

Crescent Energy Announces Accretive Eagle Ford Bolt-On; Acquires Operated Interest in Existing Non-Operated Assets

Retrieved on: 
화요일, 5월 2, 2023
Energy, Environment, Oil, Gas, LLP, CT, Kirkland & Ellis, Eagle Ford, Dallas, Line of credit, Jefferies Group, Credit Accumulation and Transfer Scheme, Acquisition, Eagle Ford Group, Gibson Dunn, Crescent, Internal, PV-10, NYSE, Cryptocurrency, Bank

Crescent Energy Company (NYSE: CRGY) (“Crescent” or the “Company”) today announced that it has entered into a definitive purchase agreement to acquire operatorship and incremental working interest in its existing Western Eagle Ford assets from Mesquite Energy, Inc. for total consideration of $600 million in cash, subject to customary purchase price adjustments.

Key Points: 
  • Crescent Energy Company (NYSE: CRGY) (“Crescent” or the “Company”) today announced that it has entered into a definitive purchase agreement to acquire operatorship and incremental working interest in its existing Western Eagle Ford assets from Mesquite Energy, Inc. for total consideration of $600 million in cash, subject to customary purchase price adjustments.
  • The accretive acquisition is consistent with Crescent’s strategy of acquiring high-value, cash flowing assets while maintaining financial strength.
  • The transaction is expected to close early in the third quarter of 2023, subject to customary closing conditions.
  • Jefferies LLC is serving as financial advisor and Gibson, Dunn & Crutcher LLP is serving as legal counsel to Mesquite.

Alpha Energy Inc. Announces Fiscal 2022 Results

Retrieved on: 
목요일, 4월 27, 2023
APHE, Bank statement, Leaver, 2016 Alpha Energy Solutions 250, Annual report, Security (finance), OK, PV-10, Renewable energy

“We are thrilled to report that 2022 was a transformative year for our company, marked by several significant milestones.

Key Points: 
  • “We are thrilled to report that 2022 was a transformative year for our company, marked by several significant milestones.
  • The Logan 1 Project had a January 1, 2022 PV-10% Proved plus Probable Reserve Valuation of $48,870,000.
  • Establishing Alpha Energy Texas Operations LLC: We organized a wholly owned bonded operator, Alpha Energy Texas Operations LLC, which will enable us to streamline our operations and enhance our control over our assets.
  • For the fiscal years ended December 31, 2022 and 2021, we reported net loss of $1,582,549 and $1,070,738, respectively.

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

Retrieved on: 
월요일, 1월 9, 2023
Disease, OS, RECIST, Knowledge, SOC, CR, CRS, Melanoma, Cancer, University, Dermatology, Particle-size distribution, Orphan Drug Act of 1983, H. Lee Moffitt Cancer Center & Research Institute, RCT, RBS, Cumming School of Medicine, Metastasis, Combination therapy, CB, SEER, Research, ITM, ORR, Hematology, III, Incidence, Progression-free survival, Classification, PFS, Neoplasm, Rockefeller University, AJCC, Infection, Prevalence, Lymph, Meta-analysis, Clinical trial, PV-10, Cell death, Standard of care, Safety, Vaccine, Diagnosis, PRN, Survival, Patient, Pembrolizumab, Medical device, Pharmaceutical industry, Medical imaging, Television, Veterinary medicine, Epidemiology, Medicine

This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.

Key Points: 
  • This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.
  • ITM diagnosis is specifically associated with an overall poor prognosis and has the potential to be seriously debilitating and life threatening.
  • Furthermore, we encourage collaboration between our various researchers to assist Provectus in building the Company’s medical science platform and associated drug pipeline.
  • Provectus’ capital raising efforts will continue in 2023.

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology

Retrieved on: 
화요일, 4월 26, 2022
Patent, Acute lymphoblastic leukemia, Epson HX-20, IL, Survival, Composition, NIH, U.S. Securities and Exchange Commission, Ophthalmology, Microbiology, Dermatology, University, Legislation, Immunotherapy, MD, USPTO, Drug discovery, GLOBE, Doctor of Philosophy, Treatment, National, Virology, P.O, Company, OTCQB, RBS, SEC, Forward-looking statement, PV-10, Method, Safety, Degenerative disease, Mouse, Oral administration, HX, Research, Pharmaceutical industry, Fine chemical, Medicine, Hematology

In vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls.1

Key Points: 
  • In vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls.1
    This allowed patent application will be the first Provectus patent award in hematology from the USPTO.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs).
  • 1 Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10 Immunotherapy for Treatments of Hematology, Oncology, and Virology.
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.

Gulfport Energy Reports Fourth Quarter and Full Year 2021 Financial and Operating Results and Provides 2022 Operational and Financial Guidance

Retrieved on: 
월요일, 2월 28, 2022
Oil, Gas, Energy, Depreciation, Income, Annual report, Investor, Natural gas, Risk, British thermal unit, Securities Exchange Act of 1934, PV-10, NGL, Company, Private Securities Litigation Reform Act, Acquisition, News, Securities Act of 1933, Forward-looking statement, Energy Independence and Security Act of 2007, Mission statement, Form 10-K, GAAP, Contract, SEC, Bank

The prices used in our PV-10 measure were $66.55 per barrel and $3.60 per MMBtu, before basis differential adjustments.

Key Points: 
  • The prices used in our PV-10 measure were $66.55 per barrel and $3.60 per MMBtu, before basis differential adjustments.
  • Gulfport will host a teleconference and webcast to discuss its fourth quarter and full year 2021 results beginning at 9:00 a.m.
  • Fourth quarter and full year 2021 earnings results and supplemental information regarding quarterly data such as production volumes, pricing, financial statements, and non-GAAP reconciliations are available on our website at ir.gulfportenergy.com .
  • It is possible that the financial and other information posted there could be deemed to be material information.

U.S. Energy Corp. Provides 2021 Year-End Proved Reserves Update

Retrieved on: 
목요일, 2월 24, 2022
Annual report, Growth, Perception, Securities Exchange Act of 1934, PV-10, U.S. Securities and Exchange Commission, Energy, Company, 8-K, Living Standards Measure, Securities Act of 1933, Forward-looking statement, Energy Independence and Security Act of 2007, Mission statement, Form 10-K, Discounting, GAAP, SEC, Bank, Security (finance)

(2) See "Alternative Year-End 2021 Estimated Proved Reserves at Strip Pricing" section below.

Key Points: 
  • (2) See "Alternative Year-End 2021 Estimated Proved Reserves at Strip Pricing" section below.
  • U.S. Energy undertakes no obligation to revise or update publicly any forward- looking statements except as required by law.
  • Our PV-10 measure and the Standardized Measure do not purport to present the fair value of our oil and natural gas reserves.
  • The following table provides a reconciliation of PV-10 of the Company's estimated proved properties to the Standardized Measure as of December 31, 2021 and not including the assets acquired in the Acquisition (in thousands):

Matador Resources Company Reports 20% Annual Increase in Total Proved Reserves, Including 56% Annual Increase in Proved Developed Reserves

Retrieved on: 
목요일, 2월 17, 2022
Oil, Gas, Natural Resources, Energy, Mining, Minerals, Other Energy, PV-10, Measure, GAAP, Atlas, Security (finance), Living Standards Measure, Bullfighter, Barrel (unit), British thermal unit, BOE, Natural gas, Sewell, Life, Industry, Oil, Renewable energy, Lithium, Airline, Delaware Basin

Total Proved Reserves at December 31, 2021 Increased 20% Year-Over-Year and Proved Developed Reserves Increased 56% Year-Over-Year

Key Points: 
  • Total Proved Reserves at December 31, 2021 Increased 20% Year-Over-Year and Proved Developed Reserves Increased 56% Year-Over-Year
    Matadors total proved oil and natural gas reserves increased 20% year-over-year from 270.3 million barrels of oil equivalent (BOE) (59% oil, 46% proved developed, 97% Delaware Basin) at December 31, 2020 to 323.4 million BOE (56% oil, 60% proved developed, 96% Delaware Basin) at December 31, 2021.
  • Oil, natural gas and total proved reserves at December 31, 2021 were each at all-time highs for Matador.
  • The increase in both Standardized Measure and PV-10 of Matadors proved oil and natural gas reserves at December 31, 2021 resulted from the increase in both oil and natural gas prices used to estimate proved reserves at December 31, 2021, as compared to December 31, 2020, but also from the increase in Matadors total proved reserves, and in particular, the Companys proved developed reserves during 2021.
  • During the year ended December 31, 2021, Matador converted approximately 40 million BOE, or 27%, of its proved undeveloped reserves at December 31, 2020 to proved developed reserves.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference

Retrieved on: 
화요일, 2월 1, 2022
Safety, Legislation, Forward-looking statement, Patient, SSAS, CT, Hematology, Clinical trial, National, Liver, PV-10, Immunotherapy, OTCQB, Adult, NET, Drug discovery, Immunogenic cell death, Microbiology, Abstract, Company, Melanoma, GLOBE, NIH, Ophthalmology, Virology, Family, Dermatology, Mnet, Wilms' tumor, PRRT, Pharmaceutical industry, Medical imaging, I25

The abstract, which was accepted for oral presentation, is entitled:

Key Points: 
  • The abstract, which was accepted for oral presentation, is entitled:
    Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy (Abstract ID: 3455, I25).
  • This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB).
  • PV-10 has been administered to over 450 patients with melanoma and cancers of the liver in both monotherapy and combination therapy settings.
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.